Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Sana Biotechnology received a “Moderate Buy” consensus rating from nine analysts: seven buys, one hold and one sell. The average 12-month price target is $9.33, compared with the stock’s recent price of $3.74.
• Institutional investors hold 88.23% of Sana’s shares, with BlackRock, Canada Pension Plan Investment Board, Bank of America and Alphabet among investors that recently acquired positions.
• Sana reported a quarterly loss of $0.13 per share, beating the analyst consensus estimate of $0.15, while analysts expect a full-year loss of $0.57 per share. The clinical-stage biotechnology company is developing engineered cell therapies for cancer, genetic disorders and other serious diseases.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $9.3333.

A number of equities analysts recently weighed in on the company. Rodman & Renshaw assumed coverage on Sana Biotechnology in a research note on Monday, May 11th. They issued a "buy" rating and a $16.00 price target on the stock. Bank of America decreased their target price on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a report on Friday, August 14th. Weiss Ratings raised shares of Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Thursday, July 23rd. Finally, Wall Street Zen downgraded shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Monday, July 20th.

Institutional Trading of Sana Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of SANA. BlackRock Inc. acquired a new stake in Sana Biotechnology during the 2nd quarter worth about $58,196,000. Canada Pension Plan Investment Board purchased a new stake in shares of Sana Biotechnology in the second quarter worth approximately $35,662,000. Bank of America Corp DE purchased a new stake in shares of Sana Biotechnology in the second quarter worth approximately $20,062,000. Alphabet Inc. acquired a new stake in shares of Sana Biotechnology during the second quarter worth approximately $9,816,000. Finally, Balyasny Asset Management L.P. acquired a new position in Sana Biotechnology in the 4th quarter valued at approximately $6,834,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Stock Performance

Sana Biotechnology stock opened at $3.74 on Friday. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -4.92 and a beta of 2.16. Sana Biotechnology has a 1 year low of $2.61 and a 1 year high of $6.55. The firm's 50 day moving average price is $3.45 and its two-hundred day moving average price is $3.42.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. As a group, equities analysts predict that Sana Biotechnology will post -0.57 EPS for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source